Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.8600 +0.0110 (+1.30%)
Streaming Delayed Price Updated: 3:12 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
30 31 Next >
Lexaria Bioscience Corp. (NASDAQ: LEXX) Publishes Eighth Peer-Reviewed Article in International Journal of Molecular Science
Via Investor Brand Network
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Building a Robust and Growing International Patent Portfolio for DehydraTECH(TM) in Support of Commercial Opportunities
Via CannabisNewsWire
Topics Intellectual Property
Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science
Via ACCESSWIRE
Lexaria Receives New Patents
Via ACCESSWIRE
Lexaria Appoints New Chief Financial Officer
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Building a Robust and Growing International Patent Portfolio for DehydraTECH(TM) in Support of Commercial Opportunities
Via Investor Brand Network
Topics Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery Sector
Via Investor Brand Network
Topics Intellectual Property
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
Via ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Study Reveals ‘Most Convincing Evidence’ of CBD’s Anti-Inflammatory Actions in Humans
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Increases Bioavailability in Lipophilic Drugs for Potential Hypertension, Epilepsy Treatments
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) – A Zacks Update
Via Investor Brand Network
Topics Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen Hormone than Control
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Published Peer-Reviewed Article on DehydraTECH(TM)-CBD, Bringing Publication Total to Eight
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Published Peer-Reviewed Article on DehydraTECH(TM)-CBD, Bringing Publication Total to Eight
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Robust Intellectual Property Portfolio to 34 Worldwide Patents with Receipt of 4 New Granted in Canada, US
Via Investor Brand Network
Topics Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands IP Portfolio with Four New Patents
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Promising Results from Diabetes Animal Study
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Promising Results from Diabetes Animal Study
Via Investor Brand Network
Topics Intellectual Property
Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study
Via ACCESSWIRE
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) May Announcements Show Resolve to Continue Supporting R&D ‘Lifeblood’
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Experienced Financial Professional as New CFO
Via Investor Brand Network
Topics Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio of Worldwide Patents
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields Most Convincing Evidence for Anti-Inflammatory Actions of CBD with its DehydraTECH(TM)-CBD
Via Investor Brand Network
Lexaria Bioscience: Exciting Drug Delivery Technology Has Potential to Disrupt Multiple Categories; Add Long Term Shareholder Value
Via AB Newswire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Animal Study Showing Its Patented DehydraTECH(TM) Technology Significantly Enhances Oral Delivery of Estradiol; Raises $2 Million in Gross Proceeds from Public Offering
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Animal Study Showing Its Patented DehydraTECH(TM) Technology Significantly Enhances Oral Delivery of Estradiol; Raises $2 Million in Gross Proceeds from Public Offering
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Finalizes DehydraTECH(TM)-CBD Batch Manufacturing for IND Filing This Summer and FDA Phase 1b Trial Commencement in October 2023
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Shareholders Approve Board Appointments Amid Push for Diversity; Vote to Endorse 6 Agenda Items in 2023 Annual Shareholder Meeting
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Findings from DehydraTECH-CBD Hypertension Study
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.